Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Protocols
Female
Fluorodeoxyglucose F18
/ pharmacology
Humans
Ipilimumab
/ administration & dosage
Male
Melanoma
/ diagnosis
Neoplasm Staging
Nivolumab
/ administration & dosage
Positron Emission Tomography Computed Tomography
/ methods
Predictive Value of Tests
Prognosis
Radiopharmaceuticals
/ pharmacology
Reproducibility of Results
Skin Neoplasms
/ diagnosis
Tomography, X-Ray Computed
/ methods
Melanoma, Cutaneous Malignant
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
3
8
2019
Statut:
ppublish
Résumé
We aimed to assess serial F-FDG PET/CT imaging according to morphological (RECIST1.1, iRECIST) and functional (PERCIST, PECRIT) criteria to predict clinical response to therapy in patients with advanced melanoma receiving immune checkpoint blocking agents.Retrospective data collection and analysis was done for 37 patients with unresectable metastatic cutaneous melanoma eligible for immunotherapy (cycles: 4 for ipilimumab and pembrolizumab/ 6 for nivolumab).F-FDG PET/CT imaging was performed prior to (F-FDG PET/CT 0) and 14 weeks after ICI onset (F-FDG PET/CT 1). Some cases during the follow-up required imaging (F-FDG PET/CT 2). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.Among 37 assessed patients, 27 had 1 line of ICI, 8 had 2 lines of ICI and 2 patients had 3 lines of ICI: total of 49 PET/CTs. Mean time between initiation of ICI and F-FDG PET/CT (1 or 2) were respectively 13.82 ± 4.32 and 24.73 ± 9.53 weeks. Time between F-FDG PET/CT 1 and F-FDG PET/CT 2 was at mean +/- SD: 11.19w ± 5.59. Median PFS was 29.62 months (range 22.52-36.71) (P = .001: RECIST 1.1), (P < .0001: iRECIST), (P = .000: PERCIST), (P = .072: PECRIT). Median OS was 36.62 months (30.46-42.78) (P = .005: RECIST 1.1), (P < .0001: iRECIST), (P = .001: PERCIST), (P = .082 PECRIT).F-FDG PET/CT could detect eventual ICI-response in patients with metastatic melanoma undergoing ICI using iRECIST and PERCIST criteria.
Identifiants
pubmed: 31335691
doi: 10.1097/MD.0000000000016417
pii: 00005792-201907190-00026
pmc: PMC6708819
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Ipilimumab
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16417Références
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10
pubmed: 18287062
Lancet Oncol. 2014 Sep;15(10):e419
pubmed: 25328942
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
J Immunother Cancer. 2014 Jun 18;2:17
pubmed: 24991412
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Ann Surg Oncol. 2001 Dec;8(10):766-70
pubmed: 11776489
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Clin Cancer Res. 2009 Jan 1;15(1):390-9
pubmed: 19118070
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):95-101
pubmed: 28831583
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
JAMA. 1998 Oct 28;280(16):1410-5
pubmed: 9801000
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Drug Des Devel Ther. 2017 Jun 13;11:1719-1728
pubmed: 28670108
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Cancer Res. 2013 Jul 15;19(14):3936-43
pubmed: 23743568
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Nucl Med. 2010 Mar;51(3):340-6
pubmed: 20150263
Nucl Med Commun. 2010 Sep;31(9):766-72
pubmed: 20585271